Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.00+0.69 (+6.10%)
Close on Nov 18, 2026Market cap $237.93MP/E –Yield –
Keros Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Keros Therapeutics's pe ratio was 4.8× on Apr 30, 2026.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 4.8× | −8.4 |
| 2025 | Dec 31, 2025 | 13.2× | – |
See a number that looks wrong?